Ameloblastin (AMBN)

Ameloblastin (AMBN) is an extracellular matrix protein predominantly expressed by ameloblasts during the formation and mineralization of dental enamel[1][2][3]. It is the second most abundant enamel matrix protein, accounting for roughly 5–10% of total enamel proteins, and is essential for proper enamel development[1][3]. Ameloblastin is involved in controlling the elongation and organization of enamel crystals, maintaining the boundary between rod and interrod enamel, and promoting adhesion and polarity of ameloblasts during enamel formation[2][3][4]. In addition to its canonical role in dental tissues, AMBN is also expressed in other tissues (such as bone and certain regions of the gastrointestinal tract), suggesting broader roles in the regulation of extracellular matrix, tissue integrity, and potentially cell signaling[5]. Pathogenic variants in the AMBN gene are associated with amelogenesis imperfecta, a genetic disorder resulting in abnormal enamel formation[1]. There are currently no drugs targeting ameloblastin, and its primary disease association is structural, not as a receptor or enzyme for pharmacological targeting. Key references: - Ameloblastin is primarily studied in the context of enamel formation and oral biology[1][2][3]. - Not classified as a traditional therapeutic target (such as a receptor, enzyme, transporter, or transcription factor)[1][2][3][4][5]. - Also known as sheathlin and amelin[1]. - Plays important roles in adhesion, differentiation, and organization of ameloblasts in developing tooth[2][3][4][6].

Other names

SheathlinAmelin